echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zejing Pharmaceutical's ZG005 powder injection clinical trial was approved by FDA

    Zejing Pharmaceutical's ZG005 powder injection clinical trial was approved by FDA

    • Last Update: 2022-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 20, Zejing Pharmaceutical announced that the clinical trial application for ZG005 powder injection has been approved by the FDA for the treatment of patients with solid tumors


    ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody powder for injection, which is classified as Class 1


    ZG005 has dual-targeted blocking of PD-1 and TIGIT.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.